Die besten Aktien des Jahres
Seite 1 von 2 Neuester Beitrag: 02.06.22 15:35 | ||||
Eröffnet am: | 30.12.02 02:36 | von: Happy End | Anzahl Beiträge: | 38 |
Neuester Beitrag: | 02.06.22 15:35 | von: Tamakoschy | Leser gesamt: | 19.167 |
Forum: | Börse | Leser heute: | 2 | |
Bewertet mit: | ||||
Seite: < | 2 > |
Trotz Bärenstimmung haben Anleger auch im Börsenjahr 2002 Gewinne erzielen können. Die Nebenwerte im MDax überraschten hingegen zum Teil mit rasanten Kurszuwächsen. Eine Tabelle der Top- und Flop-Aktien.
Hamburg – 2002 möchten die meisten Privatanleger vermutlich schnell vergessen. Was vor zwölf Monaten unmöglich schien, ist eingetroffen: Die internationalen Leitbörsen schließen das dritte Bärenjahr in Folge ab. Besonders hart getroffen wurden die deutschen Märkte.
Im Dax haben alle 30 Aktien in den vergangenen zwölf Monaten verloren. Der Index rauschte um über 40 Prozent in die Tiefe. Dabei gelten die großen Standardwerte als konservative Anlage für sicherheitsbewusste Investoren.
Verantwortlich für das dicke Minus waren vor allem die großen Technologie- und Versicherungswerte, die bis zu 80 Prozent verloren haben. Aber auch die defensiven Titel aus dem Maschinenbau- oder Konsumgütersektor verloren drastisch. Die drei besten Schwergewichte waren Henkel , Adidas Salomon und BASF , die nur Verluste bis zu fünf Prozent hinnehmen mussten.
Puma und Schwarz Pharma sind die Gewinner
Anders dagegen die Nebenwerte. Von den zehn besten Aktien aus dem Dax 100 stammen alle aus dem MDax. Ganz oben mit Kurszuwächsen von über 100 Prozent glänzen Schwarz Pharma und Puma. Dabei stand der Sportartikelhersteller bereits im vergangenen Jahr als Verdoppler auf dem Siegertreppchen.
Im laufenden Jahr hat Puma seinen Umsatz um 50 Prozent steigern können, das Ergebnis kletterte um 100 Prozent. Und ein Ende der Wachstumsstory ist noch nicht in Sicht. Zwar glauben Börsianer nicht mehr an einen weiteren Verdoppler, auf Grund der guten Geschäftsentwicklung des Adidas-Konkurrenten werden aber weitere Kurssteigerungen prognostiziert.
Ob Schwarz Pharma und Drägerwerk in den kommenden Monaten an die spektakulären Gewinne von 2002 anschließen werden, ist hingegen fraglich. Die Aktie des Pharmaunternehmens ist dank einer Medikamentenzulassung der US-Gesundheitsbehörde FDA explodiert, das Drägerwerk-Papier bekam dank seines Aufstiegs in den MDax die nötigen Impulse.
Zweistellige Zuwachsraten erzielten auch die Aktien von Leoni und Vossloh . Der Automobilzulieferer Leoni konnte die Börse vor allem mit guten Geschäftszahlen überzeugen, bei dem Bauwert Vossloh zündete die Hochwasserkatastrophe die nötige Kursfantasie.
MLP hält die rote Laterne
Starke Nerven brauchten die Aktionäre des Heidelberger Finanzdienstleisters MLP . Mit einem Minus von über 80 Prozent führt das Papier die Verliererliste im Dax 100 an. Auslöser der Kurserosion: Das Unternehmen soll mit fragwürdigen Bilanzierungsmethoden den Markt getäuscht haben. Zwar hat MLP die Anschuldigungen zurückgewiesen, seit dem Bilanzskandal um Enron wird an der Börse aber alles abgestraft, was nicht 100-prozentig sauber scheint.
Ebenfalls Opfer der miserablen Börsenstimmung ist die Beteiligungsgesellschaft WCM geworden. Mit einem Minus von annähernd 80 Prozent ist das Unternehmen der größte MDax-Verlierer. Aber auch die Allianz (rund minus 60 Prozent) und die Münchener Rück (rund minus 55 Prozent) sind von den Bären zerpflückt worden.
Eine zweite Branche, die extreme Kursrückgänge verbucht hat, ist der Technologiesektor. Epcos rutschte um über 70 Prozent in den Keller, Infineon gab mehr als 65 Prozent ab. Immer noch leiden die Hightechs unter der Kursblase und den aufgebauten Überkapazitäten. Und immer noch ist keine Trendwende in Sicht. Zwar erwarten Börsianer keine drastischen Kursrückgänge mehr, auf eine Erholung der gebeutelten Branche setzen aber nur wenige.
* Zur Berechnung wurden die Xetra-Schlussstände vom 2. Januar 2002 bis 11. Dezember 2002 herangezogen |
Medifast hat Anfang des Jahres 0,27 gekostet.
Gruss E.
http://chart.bigcharts.com/bc3/quickchart/...83&mocktick=1&rand=6710"
Gruss E.
TOP 10
Firstwave Technologies (FSTW: news, chart, profile). The runaway best performer this year is a tech stock - but one on the rebound. Shares of the customer relationship management software developer doubled in one day after reporting a profit for the first quarter, reversing a year-ago loss and tripling profits sequentially. Revenue rose by 152 percent. In the second quarter, Firstwave had a profit vs. a loss a year ago, while revenue again soared, by 128 percent. For the year, Firstwave shares have risen by 1,080 percent to $12.16.
Netease.com (NTES: news, chart, profile). Netease, one of two dot-coms that made it to the top 10 list, is one of China's "Big Three" Web portals. While U.S. Internet companies have fallen out of favor with investors, their Chinese counterparts have enjoyed a surge of activity not seen since the go-go days of the late 1990s. See story. Not only are the top Chinese portals reducing their reliance on online ads, they are getting more financially fit. Last month, Beijing-based Netease reported an operating profit. It also doesn't hurt that China has a booming economy. Shares have risen 1,000 percent gain to $9.97.
USANA Health Sciences (USNA: news, chart, profile). Getting fit is in. Shares of the nutrition and weight management products seller rose by almost 860 percent this year to $11.59. This week, USANA raised its earnings forecast for the fourth quarter, driven by an expansion into Taiwan. It now expects to earn 26 to 28 cents a share, up from its prior estimate of 20 to 22 cents. Sales should top $37 million, the highest quarterly sales ever at USANA. It's a repeat performance - the company had raised its third-quarter outlook as well.
Rural/Metro Corp. (RURL: news, chart, profile). One of the nation's largest ambulance service providers, Rural/Metro saw its shares rise by almost 560 percent this year as its bottom line steadily improved. Last week, the company was able to extend the maturity date of $152 million in debt to the end of 2004. To cut costs, Rural/Metro sold discontinued its operations in Latin America, including those in Argentina and Bolivia, due to the economic decline in the region.
Catalina Lighting (CALA: news, chart, profile). "Fiscal 2002 was a watershed year for Catalina," said CEO Eric Bescoby. Indeed, it marked the return to profitability by the lighting products maker. Operating costs fell while debt was reduced by nearly 40 percent - paid off with funds from the sale of a Mississippi warehouse, improved cash flow and conversion of debt to equity by the majority shareholder. Investors responded by bidding up shares by 487 percent this year.
Hecla Mining (HL: news, chart, profile). The top ten list wouldn't be complete without a gold mining company, thanks to the torrid performance of the yellow metal. This week, gold soared to as high as $355 an ounce on growing concern of a U.S. war with Iraq. Higher gold prices helped catapult Hecla Mining to the number six spot among 2002's best performers. Shares are up 422 percent to $4.91.
Lannett Co. (LCI: news, chart, profile). The generic drugs maker kicked butt this year and is off to a roaring start in fiscal 2003. Lannett reported a 108 percent increase in net sales for fiscal 2002 while the net income soared by nearly 380 percent. - its best results in 60 years of company history. For the first quarter of fiscal 2002, sales rose by 124 percent and profits by nearly 180 percent. The stock has likewise responded: Up 410 percent for the year to $17.85.
Clean Harbors (CLHB: news, chart, profile). Shares of the hazardous waste management company skyrocketed by nearly 60 percent in one day after declaring that fourth-quarter revenue would increase by at least 131 percent from a year ago and 2003 profits would range from $2 to $2.06 a share - up from the expected 17 cents for 2002. Revenues are forecasted to triple next year. Clean Harbors also stands to cut costs through its purchase of the chemical services division of Safety-Kleen. This year, the stock gained 404 percent to $16.99.
Reliv International (RELV: news, chart, profile). Americans' increased focus on health has boosted the fortunes of Reliv, a maker of food supplements, diet management products and sports drinks. This week, the company said it expects to post a more than 17-fold gain in profits for the fourth quarter and a nearly eight-fold gain in earnings for the year. Investors gobbled up the shares, up 375 percent to $5.
Ebookers plc (EBKR: news, chart, profile). Europeans took to the Internet for their travel plans, bidding up shares of the UK-based online travel agent by 367 percent this year. See story. Last month, the company said its third-quarter earnings before interest, taxes, depreciation and amortization (EBITDA) was positive for the first time ever, despite a tough travel market after Sept. 11. Gross sales rose by 58 percent year-over-year while the net loss narrowed substantially.
BOTTOM 10
AirGate PCS (PCSA: news, chart, profile). An affiliate of Sprint PCS, the regional wireless phone company sells mobile services under the Sprint brand in seven states in the Southeast and Midwest. On June 6, the stock lost two-thirds of its value after AirGate slashed growth expectations due to tough market conditions. A slew of downgrades followed. In September, Standard & Poor's cut the firm's corporate credit rating over concerns about liquidity, distracted management and lackluster cash flow. In 2002, shares fell 98 percent to 81 cents.
Ntelos Inc. (NTLO: news, chart, profile). Once a rural phone company called CFW Communications, Ntelos now is a diversified telecom services provider. But shares have fallen by 97.8 percent this year to 34 cents on concerns about its liquidity and ability to meet bank loan conditions. Last month, Standard & Poor's cut its corporate credit rating, saying that cash flow improvement from the wireless business in 2003 is not expected to be enough to meet Ntelos' financial covenants. Moreover, S&P said the business risk for regional wireless telecom firms has increased materially, with aggressive marketing by national carriers and entry of new regional competitors.
Spectrum Pharmaceuticals (SPPI: news, chart, profile). Formerly Neotherapeutics, the biotech company is worth more liquidated. See Sophisticated Investor. Shares are down 97.7 percent this year to $2.04. The company initially worked on treatments for central nervous system (CNS) conditions. But clinical trials for its Neotrofin drug for Alzheimer's disease showed that the treatment failed to achieve statistical significance over the placebo - and shares fell 67 percent in one day. Spectrum has switched to the cancer treatment market, offering its Satraplatin drug to fight prostate cancer.
DDi Corp. (DDIC: news, chart, profile). Shares of the contract manufacturer of electronics products dove 97 percent to 22.5 cents. Like its peers, the company is struggling against a slump in the tech market. DDi is restructuring operations and cutting costs, part of which came from job cuts. The company also had amended its credit line agreements.
Telewest Communications plc (TWSTY: news, chart, profile). Earlier this year, shares of the UK's second largest cable television operator plunged on concerns that bondholders would end up owning most of the company in return for forgiving debt. It turned out to be true. Last month, the Deal.com reported that Telewest was close to securing a $5.5 billion debt-to-equity swap deal with its bankers. Under the terms of the agreement, Telewest shareholders would own 3 percent of the company with the rest going to bondholders. Liberty Media (L: news, chart, profile) and Microsoft (MSFT: news, chart, profile) each hold a 25 percent stake. The stock is down 96.9 percent this year to $5.85.
Storage Computer Corp. (SOS: news, chart, profile). This data storage firm needs help from the tech downturn. Last month, Storage Computer reported a third-quarter net loss of $5.3 million vs. a loss of $3.7 million. Sales shriveled to $620,000 from $2 million. The company just lost a patent infringement lawsuit filed in the UK against Hitachi Data Systems. Shares are down 96.8 percent this year to 20 cents.
British Energy (BGY: news, chart, profile). The holding company for British Energy Generation provides 20 percent of power in the United Kingdom through eight nuclear plants. But falling electricity prices and technical problems at its power stations have hurt the bottom line. In November, the company said it must restructure to avoid bankruptcy. The British government has agreed to underwrite the cost of decommissioning its nuclear plants and extended an emergency loan. Shares dove 96.7 percent this year to 44 cents.
Net Servicos de Comunicacao (NETC: news, chart, profile). Formerly Globo Cabo, the company is Brazil's largest cable TV operator. But shares plunged as business weakened from a slump in Latin America's biggest economy. Also, the depreciation of Brazil's currency magnified the company's debt. The stock fell 96.6 percent to $1.18.
Sheffield Pharmaceuticals (SHM: news, chart, profile). The biotech company needs treatment of its own. Last month, Sheffield warned that it is in danger of ceasing operations since cash levels have dwindled to $700,000 while accounts payable and accrued liabilities top nearly $3 million. In the third quarter, the company lost $1.9 million - more than the amount of its total assets. Sheffield is developing drugs for the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary afflictions and cystic fibrosis. The stock has fallen by 96.5 percent to 16 cents a share.
Sba Communications (SBAC: news, chart, profile). Shares of the wireless tower provider are down 96.2 percent this year to 49 cents over liquidity concerns. Sba has more than $1 billion in debt and is in danger of violating bank covenants as earnings dropped due to order cutbacks by wireless carriers, according to Standard & Poor's. With spending by carriers expected to remain weak in 2003, the company may not be able to improve profits materially since it has already taken major cost-cutting measures.
Deborah Adamson is a reporter for CBS.MarketWatch.com in Los Angeles.
Wer hat zugegriffen? Ich leider nicht, so ein Pech aber auch!
MfG
opa_kosto
02 + 291% EBOOKERS
02 + 218% BETA SYSTEMS
02 + 158% CONDAT
02 + 144% BRAU UND BRUNNEN
02 + 105% SALAMANDER
02 + 85% KINOWELT
02 + 84% REINHOLD UND MAHLA
02 + 79% AD PAPPER
02 + 66% TELEGATE
02 + 59% UNITED INTERNET
02 + 55% VIZRT
02 + 52% TELES
02 + 51% DINO
02 + 48% MICRONAS
02 + 46% HEILER
02 + 41% INTERTAINMENT
02 + 40% COMPUTEC MEDIA
Ist datt nix?
Dazu noch die Dividenden Hits von
14% - NORDWEST HANDEL
13% - LUDWIG BECK
12% - MINERAL. ÜBERKINGEN VZ
9% - AHLERS
9% - BIEN HAUS
9% - ELECTRONICS LINE
8% - MPC
8% - KLÖCKNER
8% - CURANUM
8% - SIXT VZ
8% - WMF VZ
"Dabei statt mittendrin"!
Gr.Gr.;-)
die Aktie ?
http://chart.bigcharts.com/bc3/quickchart/...044&mocktick=1&rand=908"
Gruss E.
Usana rennt auch davon, meinst Du die schaffen 30 Dollar?
Grüße
Pavian
Für HITK musste man gestern 38,40 Dollar hinblättern, der Chart von USNA sieht identisch aus.
Gruss E.
http://chart.bigcharts.com/bc3/quickchart/...065&mocktick=1&rand=284"
Gruss E.
http://chart.bigcharts.com/bc3/quickchart/...40&mocktick=1&rand=8785"
http://chart.bigcharts.com/bc3/quickchart/...241&mocktick=1&rand=397"
Dennis Slothower Highlights the Following Stocks: Netflix, Closure Medical Corporation, and Medifast
WEDNESDAY, MAY 21, 2003 6:00 AM
- BusinessWire
CHICAGO, May 21, 2003 (BUSINESS WIRE) -- Dennis Slothower urges patience as the market looks to pull back in the coming weeks. But that buy signal is right around the corner, and you could be prepared with three stocks whose performances have been anything but patient. Learn about Netflix (NFLX) , Closure Medical Corp (CLSR) and Medifast, Inc. (MED) . Click here for the full story exclusively on Zacks.com: http://featuredexpert2bw.zacks.com/
Here are the highlights from the Featured Expert column:
We are now entering into a seasonally weak period. Dennis Slothower is looking for a pullback that should last for a few weeks, and then we should be off to the races again, with higher highs in the cards. This is a confusing time for investors. Bond and currency traders appear to be thinking the economy is about to get bad, while stock traders appear to think that the economy will start to improve in six months or so. In reality, both could be right. In the meantime, Dennis wants you to be patient.
Dennis has had a number of success stories in the "stocks that can double" section of the letter. Three, in particular, have done very well. Netflix (NFLX) , Closure Medical Corp (CLSR) and Medifast, Inc. (MED) all just about doubled from their first mention in the February and March issues.
Dennis particularly likes Medifast, which at one point was up 98% recently before profit taking developed. This is a company that he thinks has a very bright future. MED announced that revenues more than doubled from year-earlier periods. The company generated a 258% increase over last year and 41% over last quarter; with pre-tax income growth of 415% from 2002's first quarter; and cash increases by 90% since year-end.
Be ready for the next buy signal with Dennis Slothower's portfolio recommendations by clicking: http://featuredexpert3bw.zacks.com/
About Zacks Featured Experts
To be a successful investor you need professional advice. Experts who know what they're talking about and can help you achieve your financial goals in good markets...and especially in bad ones will help you improve your portfolio. That is why Zacks Investment Research has assembled the best investment experts in the business to offer their powerful advisory newsletters to you on all the major investment topics: Stocks, Mutual Funds, Bonds, Options, Futures etc.
Recommendations from Featured Experts Highlighted in FREE Investment Newsletter
The best way to tap into the powerful advice from these experts is through our free weekly e-mail newsletter, "Profit from the Pros". Each week we highlight several Featured Experts in this free e-mail newsletter. Get your free subscription to "Profit from the Pros" at: http://www.freeprofit1bw.zacks.com
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1981 to compile, analyze, and distribute investment research to both institutional and individual investors. The guiding principle behind our work is the belief that investment experts, such as brokerage analysts and investment newsletter writers, have superior knowledge about how to invest successfully. Our goal is to unlock their profitable insights for our customers. And there is no better way to enjoy this investment success, than with a FREE subscription to "Profit from the Pros" weekly e-mail newsletter. For your free newsletter, visit http://www.freeprofitbw.zacks.com
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
SOURCE: Zacks.com
Zacks.com
Terry Batey, 312-630-9880 x 307
feedback@zacks.com
www.Zacks.com
10%
100%
1000%
ich kauf mir ein Haus und stell
mir 2oder 4 Ferraris davor.......
...kenn ich.....
Darum Jungs:
auch mal knete mitnehmen &&&&&
ZU SEITE LEGEN!!!!
bei mir hatt's (genau so ) geklappt.
Waldy
Ich gehe noch arbeiten, bin nur Hobbybörsianer.
Viel Erfolg noch mit Medion und GPC.
Gruss E.
aber auch ich, hab schon heulend unter'n Bett
gelegen ,und nach meiner Mama gerufen....
mann braucht Glück! (eine gute Nase ist auch prima)
Waldy
Ps.
Champion? eher Pilz ( Ngelpilz)
Mitarbeiteranzahl : 713 Personen.
https://de.marketscreener.com/kurs/aktie/...ST-INC-31881/unternehmen/
https://seekingalpha.com/news/...st-eps-beats-by-066-beats-on-revenue
https://seekingalpha.com/article/...-results-earnings-call-transcript
Zahlen & Ausblick sind hervorragend
Zeitpunkt: 07.10.21 09:16
Aktion: Löschung des Beitrages
Kommentar: Moderation auf Wunsch des Verfassers